GTx: Enobosarm trials
GTx Inc. (NASDAQ:GTXI) is a Memphis-based microcap biopharmaceutical company that has a large pipeline of Selective Androgen Response Modifiers (SARMs), which are androgen (male hormone) analogues. GTx has just completed two Phase III (P3) clinical trials of its lead drug, enobosarm, called POWER 1 and POWER 2. A "data lock" was placed in May, allowing the data to be analyzed. The two primary endpoints of the enobosarm POWER trials were to stabilize or improve lean body muscle (LBM) wasting (sarcopenia); and physical function (strength), in patients with advanced, Stage 3/4, non-small cell lung cancer (NSCLC). Muscle loss occurs very early in the cancer process, and, in fact, it is broken down preferentially over fat,...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|